This finding was confirmed for both de novo and s-AML patients; the variant T allele was found to be 1.5- and 2.4-fold higher in de novo and s-AML respectively than the control group, indicating a possible effect of the G516T CYP2B6 germline polymorphism on AML susceptibility. The gene discussed is CYP2B6; the disease is acute myeloid leukemia.